abstract |
A topical intranasal antiviral composition for protecting against virus infections. The composition comprises an antigen binder and a pharmaceutical suspender material to allow effective delivery into the nasal cavity. Examples of materials that could be used in the pharmaceutical suspender are microcrystalline cellulose or sodium carboxymethylcellulose (Na∙CMC). One particular target for the antigen binder could be SARS-CoV-2. For example, the antigen binder could target the S1 subunit of SARS-CoV-2. The composition could be made by a process in which the pharmaceutical vehicle is prepared, and then the antigen binder is added to the pharmaceutical vehicle to make a bioactive mixture, and then adding solid sodium chloride to the bioactive mixture. Also disclosed are methods of protection against virus infection using the intranasal antiviral composition. For example, in the case of SARS-CoV-2, the antigen binder would block the virus particles from attaching to ACE2 receptors on host cells of the nasal mucosa or nasopharynx. This blocking action would protect against virus infection. |